Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634669 · ClinicalTrials.gov registry record · Phase 2
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
A Phase 2 study, sponsored by Axsome Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT04634669 is a Phase 2 study that was terminated before completion, run by Axsome Therapeutics. The registered enrollment target is 181 participants.
The verdict
NCT04634669, a Phase 2 study, was terminated before completion, sponsored by Axsome Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
Interventions
- DRUG AXS-05 (dextromethorphan-bupropion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2022-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634669
The ClinicalTrials.gov registry entry for NCT04634669 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AXS-05 (dextromethorphan-bupropion) is the first listed.
NCT04634669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04634669 about?
NCT04634669 is a clinical study titled "Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)". This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
What is the current status of trial NCT04634669?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2020-09-23. Estimated completion is 2022-03-04.
What interventions are being tested in trial NCT04634669?
The interventions under investigation include: AXS-05 (dextromethorphan-bupropion) (DRUG).
Who is sponsoring clinical trial NCT04634669?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.